FDA Brief

Warning letters Drugs

FDA warning letter to

A. Nelson & Co. Ltd.

High riskIssued Feb 12Posted Feb 24Center for Drug Evaluation and Research (CDER)

London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.

What happened

FDA inspected the company's London drug manufacturing facility from September 15 to 19, 2025. Investigators found batches of homeopathic drugs, including products labeled for children as young as two, released without testing for objectionable microorganisms, and expiration dates extended without stability data to support them. FDA also found that quality records, including analytical forms with failing results, were discarded, and one batch was detained and refused admission at the U.S. border after FDA testing found microbiological contamination.

What FDA found

  1. The company released batches of drug product without testing each batch to confirm it was free of objectionable microorganisms.

    21 CFR 211.165(b)
  2. The company extended expiration dates beyond what its stability data supported, so shelf-life claims were not backed by evidence.

  3. The quality unit lacked adequate written procedures and oversight, and CGMP records such as manufacturing records and finished product specification forms were not properly kept.

    21 CFR 211.22(d)
  4. An out-of-trend result noted on a handwritten sticky note was found among discarded materials and was never documented or investigated.

    21 CFR 211.22(d)
  5. Duplicate records were printed without a procedure to track issuance and reconciliation, and analytical forms with unacceptable results were thrown away instead of triggering investigations.

    21 CFR 211.22(d)

What FDA wants

FDA tells the company to respond in writing within 15 working days describing what it has done and will do to fix these violations and prevent recurrence. The letter also asks for full chemical and microbial testing of retain samples, a quality unit assessment and remediation plan, a data integrity investigation and risk assessment, and a qualified CGMP consultant to perform a six-system audit.

Who should pay attention

  • brands and distributors selling homeopathic or children's remedies made by this contract manufacturer
  • U.S. importers and retailers of UK-made homeopathic drugs
  • companies that rely on a supplier's batch release and stability data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk